Comparison of the vasodilatory effects of vasoactive intestinal polypeptide (VIP) and peptide-HI (PHI) in the rabbit and the cat.

Nilsson SF, Mäepea O

Acta physiologica Scandinavica1 Jan 1987Cited by 18 (Europe PMC)

PMID3565040DOI10.1111/j.1748-1716.1987.tb08035.xPepBankPUB-03565040

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, intravenous VIP increased choroidal blood flow by about the same amount as PHI.
In plain wordsIn rabbits, VIP raised blood flow in the choroid of the eye about as much as PHI did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseChoroidal blood flow
Study
rabbitn: not reported in source
anaesthetized rabbit, radioactive microspheres
Comparator
PHI
Outcome group
Vascular function · Cardiovascular
Studied dose
60 pmol kg-1 min-1 · intravenousAs given in this study (rabbit).
Source sentences
Summary
Determination of local blood flows, with radioactive microspheres, showed that i.v. infusion of VIP or PHI (60 pmol kg-1 min-1) caused about the same increase in the choroidal blood flow
Report a problemFND-0356504001
02AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, intravenous VIP did not change local blood flow in the anterior uvea.
In plain wordsIn rabbits, VIP did not change blood flow in the front part of the eye.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeBlood flow in the anterior uvea
Study
rabbitn: not reported in source
anaesthetized rabbit, radioactive microspheres
Outcome group
Vascular function · Cardiovascular
Studied dose
60 pmol kg-1 min-1 · intravenousAs given in this study (rabbit).
Source sentences
Summary
while the local blood flow in the anterior uvea was unaffected by both peptides
Report a problemFND-0356504002
03AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, intravenous VIP had its most marked effect in glandular tissues, such as the pancreas, submandibular, parotid and thyroid glands.
In plain wordsIn rabbits, VIP had its strongest effect on blood flow in gland tissues such as the pancreas and thyroid.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseBlood flow in glandular tissues
Study
rabbitn: not reported in source
anaesthetized rabbit
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rabbit).
Source sentences
Summary
The most marked effect of VIP was observed in glandular tissues, such as the pancreas, submandibular, parotid and thyroid glands.
Report a problemFND-0356504003
04AnimalAnimal study (in vivo)Efficacy outcome
In cats, intravenous VIP infusion markedly increased blood flow in several tissues.
In plain wordsIn cats, a short VIP infusion clearly raised blood flow in several tissues.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseRegional blood flow in several tissues
Study
catn: not reported in source
anaesthetized cat
Outcome group
Vascular function · Cardiovascular
Studied dose
30 pmol kg-1 min-1 · intravenous · 5-7 minAs given in this study (cat).
Source sentences
Summary
In cats, i.v. infusion of VIP (30 pmol kg-1 min-1) during 5-7 min caused a markedly increased blood flow in several tissues.
Report a problemFND-0356504004
05AnimalAnimal study (in vivo)Efficacy outcome
In cats, the VIP-induced vasodilation in glandular tissues was more marked than in rabbits.
In plain wordsIn cats, VIP widened blood vessels in gland tissues more than it did in rabbits.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseBlood flow in glandular tissues of cats
Study
catn: not reported in source
anaesthetized cat
Outcome group
Vascular function · Cardiovascular
Studied dose
30 pmol kg-1 min-1 · intravenous · 5-7 minAs given in this study (cat).
Measurements
Glandular blood flow
3 to 15 times normal
cat
Source sentences
Summary
The vasodilation in glandular tissues was even more marked than in rabbits; 3-15 times the normal compared with two to five times the normal in rabbits.
Report a problemFND-0356504005
06AnimalAnimal study (in vivo)Efficacy outcome
In cats, intravenous VIP significantly decreased choroidal blood flow.
In plain wordsIn cats, VIP lowered blood flow in the choroid of the eye.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseChoroidal blood flow in cats
Study
catn: not reported in source
anaesthetized cat
Outcome group
Vascular function · Cardiovascular
Studied dose
30 pmol kg-1 min-1 · intravenous · 5-7 minAs given in this study (cat).
Source sentences
Summary
The choroidal blood flow was however significantly decreased
Report a problemFND-0356504006
07AnimalAnimal study (in vivo)Efficacy outcome
In cats, local blood flow in the anterior uvea tended to be reduced by VIP, without a significant change.
In plain wordsIn cats, blood flow in the front part of the eye tended to fall with VIP, but not clearly.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeAnterior uveal blood flow in cats
Study
catn: not reported in source
anaesthetized cat
Outcome group
Vascular function · Cardiovascular
Studied dose
30 pmol kg-1 min-1 · intravenous · 5-7 minAs given in this study (cat).
Source sentences
Summary
the local flow in the anterior uvea tended also to be reduced.
Report a problemFND-0356504007
08AnimalAnimal study (in vivo)Efficacy outcome
In cats, a higher VIP dose given for a short infusion had no effect on uveal vascular resistance.
In plain wordsIn cats, a higher VIP dose did not change resistance to blood flow in the eye.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeUveal vascular resistance at higher VIP dose
Study
catn: not reported in source
anaesthetized cat
Outcome group
Vascular function · Cardiovascular
Studied dose
60 pmol kg-1 min-1 · intravenous · 2 minAs given in this study (cat).
Source sentences
Summary
Intravenous infusion of either a higher dose of VIP (60 pmol kg-1 min-1) or of PHI (1800 pmol kg-1 min-1) during 2 min had no effect on the uveal vascular resistance.
Report a problemFND-0356504008
09AnimalAnimal study (in vivo)Efficacy outcome
In rabbits and cats, porcine VIP was a more potent vasodilator than porcine PHI in most tissues, with exceptions such as the rabbit uvea.
In plain wordsIn rabbits and cats, VIP widened blood vessels more strongly than PHI in most tissues, but not in the rabbit eye.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVasodilator potency of VIP versus PHI
Study
rabbit and catn: not reported in source
anaesthetized rabbit and cat
Comparator
Porcine PHI
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rabbit and cat).
Source sentences
Summary
porcine VIP is a more potent vasodilator than porcine PHI in most tissues of both the cat and the rabbit, but that there may be exceptions such as the rabbit uvea
Report a problemFND-0356504009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.